The effects of ApoE gene polymorphisms on lumbar spine bone mineral density and carotid atherosclerosis

Jianming Hou1, Huinan Wu

  • 1Department of Endocrinology, Provincial Clinic College of Fujian Medical University, Provincial Hospital of Fujian, Fuzhou 350001, China. hjm996@yahoo.com.cn

Clinical Biochemistry
|December 20, 2011
PubMed

Insights

The ApoE4 genotype is linked to carotid atherosclerosis in elderly men, but not to reduced bone mineral density in the lumbar spine. This suggests ApoE4 influences vascular health independently of bone density.

Area of Science:

  • Genetics
  • Cardiovascular Medicine
  • Osteoporosis Research

Background:

  • Carotid atherosclerosis (CA) and osteoporosis are common in elderly populations.
  • The role of ApoE gene polymorphisms in these conditions requires further investigation.

Purpose of the Study:

  • To investigate the correlation between osteoporosis and carotid atherosclerosis (CA).
  • To explore the effects of ApoE gene polymorphisms on lumbar spine bone mineral density (BMD) and CA in elderly Han males.

Main Methods:

  • A study involving 221 elderly Han males.
  • Participants were categorized into control, CA, low BMD, and combined CA/low BMD groups.
  • ApoE gene polymorphisms were analyzed in all groups.

Main Results:

  • The incidence of ApoE4 isoforms was significantly higher in the CA group compared to controls (P<0.05).
  • No significant differences in ApoE4 isoform or genotype incidence were observed between the low BMD groups (BMD↓ and CA+BMD↓) and the control group.
  • ApoE4 genotype incidence did not differ significantly across the CA, BMD↓, and CA/BMD↓ groups.

Conclusions:

  • The ApoE4 genotype may serve as a risk factor for developing carotid atherosclerosis.
  • The ApoE4 genotype does not appear to be correlated with bone mineral density in the lumbar spine of elderly Han males.
Abstract

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...